Presence of risk factors associated with colectomy among patients with ulcerative colitis: a post hoc analysis of data from the tofacitinib OCTAVE ulcerative colitis clinical program

BACKGROUND: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). OBJECTIVE: To assess colectomy incidence rates (IRs) and baseline characteristics for the presence of identified colectomy risk factors among patients in the tofacitinib OCTAVE UC c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rubin, David T., Salese, Leonardo, Cohen, Mitchell, Kotze, Paulo G., Woolcott, John C., Su, Chinyu, Mundayat, Rajiv, Paulissen, Jerome, Torres, Joana, Long, Millie D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408314/
https://www.ncbi.nlm.nih.gov/pubmed/37560161
http://dx.doi.org/10.1177/17562848231189122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408314/
https://www.ncbi.nlm.nih.gov/pubmed/37560161
http://dx.doi.org/10.1177/17562848231189122

Ejemplares similares